RxDoctor Payments Data

Monika Jarzmik

Family · Idaho Falls, IDNPI 1053726497

Payments from drug & device makers

$585in general payments, 2019–2025

Across 20 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$308
  • Amgen$92
  • Boehringer Ingelheim$56
  • AbbVie$35
  • Sandoz$17
  • GSK$17
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$28449%
  • Education$30151%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson5$308
Amgen(2 entities)6$92
Boehringer Ingelheim1$56
AbbVie2$35
Sandoz1$17
GSK1$17
Fresenius Kabi USA, LLC1$16
AstraZeneca1$16
UCB, Inc.1$15
Novartis1$14

How this compares

$585 in reported general payments places this provider in the 60th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$152,641
Medicare patients
327
Services billed
7,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab77$515,437
Enbrel SureclickEtanercept68$492,044
RinvoqUpadacitinib27$168,603
Humira(Cf)Adalimumab23$155,833
Xeljanz XrTofacitinib Citrate18$134,299
Cosentyx Sensoready (2 Pens)Secukinumab14$122,085
Orencia ClickjectAbatacept15$107,240
Taltz AutoinjectorIxekizumab16$105,423
Cosentyx Unoready PenSecukinumab12$95,595
BenlystaBelimumab13$62,107
KevzaraSarilumab14$59,723
Leflunomide78$13,000
Hydroxychloroquine Sulfate178$7,520
MethotrexateMethotrexate Sodium256$5,641
Leucovorin Calcium103$3,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$35$324,43550 claims
GSKBenlysta$17$62,10713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 809 family providers in Idaho.

Other family in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →